<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Strides Arcolab Ltd. | Company News & Executive Profiles | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/strides+arcolab+ltd..html?i=12]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Strides Arcolab Ltd.]]></description>
	<s:counts start="0" returned="10" found="18" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces FDA Approval for Pamidronate Disodium Injection, 3 mg/mL and 9 mg/mL]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Nov_3/ai_n30959079]]></link>
		<description><![CDATA[LAKE FOREST, Ill. -- Akorn-Strides, LLC today announced that the U.S. Food and Drug Administration has granted approval for an Abbreviated New Drug Application ANDA for Pamidronate Disodium Injection, 3 mg/mL and 9 mg/mL in 10 mL vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2004 by...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 03 Nov 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces FDA Approvals for Dexamethasone Sodium Phosphate Injection USP, 4 mg /mL and Dexamethasone Sodium Phosphate Injection USP, 10 mg /mL]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Sept_2/ai_n28048061]]></link>
		<description><![CDATA[BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approval of two ANDAs for Dexamethasone Sodium Phosphate Injection USP, 4 mg base/mL in 1mL, 5 mL, and 30 mL vials, and Dexamethasone Sodium Phosphate Injection USP, 10 mg base/mL in 10 mL vials. Akorn-Strides, LLC is a Joint Venture that...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 02 Sep 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces the First Commercial Product Launch for the Joint Venture, Rifampin for Injection]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_July_11/ai_n27909138]]></link>
		<description><![CDATA[BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the first commercial product launch for the Joint Venture, Rifampin for Injection USP, 600 mg/vial. Rifampin is used in the treatment of all forms of tuberculosis in conjunction with Isoniazid and Ethambutol.  To date, the company has filed for 18 ANDAs...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 11 Jul 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces FDA Approvals for Famotidine Injection USP, 20 mg/2mL Single-Dose Vials and Famotidine Injection USP, 40 mg/4mL & 200 mg/20 mL Multiple-Dose Vials]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_26/ai_n27871185]]></link>
		<description><![CDATA[BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approvals of two ANDAs for Famotidine Injection USP, 20 mg/2mL Single-Dose Vials and 40 mg/4mL & 200 mg/20mL Multiple-Dose Vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited (NSE:...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 26 Jun 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces FDA Approval for Rifampin for Injection USP, 600 mg/Vial]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_23/ai_n25452520]]></link>
		<description><![CDATA[BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approval of an ANDA for Rifampin for Injection USP, 600 mg/vial. This is the first lyophilized Injectable product approval for the Joint Venture.  Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 23 May 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces FDA Approval for Flumazenil Injection USP, 0.1 mg/mL - 5mL and 10 mL Multiple Dose Vials]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_May_14/ai_n25411880]]></link>
		<description><![CDATA[BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approval of an ANDA for Flumazenil Injection USP, 0.1 mg/mL, packaged in 5 mL and 10 mL Multiple Dose Vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ:AKRX) and Strides Arcolab Limited (NSE:STAR) (BSE:532531)....]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 14 May 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces FDA Approvals for Ondansetron Injection USP, 4 mg/2mL Single Dose Vials and Ondansetron Injection USP, 40 mg/20mL Multiple Dose Vials]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_24/ai_n25355313]]></link>
		<description><![CDATA[BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approvals of two ANDAs for Ondansetron Injection USP, 4 mg/2mL Single Dose Vials and Ondansetron Injection USP, 40 mg/20mL Multiple Dose Vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 24 Apr 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces FDA Approval for Fosphenytoin Sodium Injection USP, 100 mg/2mL and 500 mg/10mL]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_March_19/ai_n24928492]]></link>
		<description><![CDATA[BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approval of an ANDA for Fosphenytoin Sodium Injection USP, 100 mg/2mL and 500 mg/10mL equivalent to Phenytoin Sodium. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ:AKRX) and Strides Arcolab Limited (NSE:STAR) (BSE:532531). The primary...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 19 Mar 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces FDA Approval for Tobramycin Injection USP, 80 mg/2mL and 1.2 grams/30mL]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_March_11/ai_n24384813]]></link>
		<description><![CDATA[BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced the approval of an ANDA for Tobramycin Injection USP, 80 mg/2mL and 1.2 grams/30mL. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited (NSE: STAR, BSE: 532531). The primary mission for...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 11 Mar 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
	<item>
		<title><![CDATA[Akorn-Strides, LLC Announces its First ANDA Approval For Keterolac Tromethamine Injection USP, 15 mg/mL and 30 mg/mL]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_July_17/ai_n27312378]]></link>
		<description><![CDATA[BUFFALO GROVE, Ill. -- Akorn-Strides, LLC today announced its first ANDA approval for Keterolac Tromethamine Injection USP, 15 mg/mL and 30 mg/mL. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited (NSE: STAR)(BSE: 532531). The primary mission for the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 17 Jul 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/akorn+inc..html"><![CDATA[Akorn Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/strides+arcolab+ltd..html"><![CDATA[Strides Arcolab Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AKRX</category>
		<category domain="tickers">AKRX</category>
	</item>
</channel>
</rss>
